{
    "code": "02022473",
    "url": "http:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02022473",
    "time": "2017-04-07 03:27:59",
    "許可證字號": "衛署藥輸字第022473號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "108\/05\/04",
    "發證日期": "88\/05\/04",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202247306",
    "中文品名": "抗癌妥靜脈輸注濃縮液",
    "英文品名": "CAMPTO CONC. SOLUTION FOR I.V. INFUSION",
    "適應症": "晚期性大腸直腸癌之第一線治療藥物：\r\n與5-FU及folinic acid合併，使用於未曾接受過化學治療之患者。\r\n單獨使用於曾接受5-FU療程治療無效之患者。\r\n與cetuximab併用，治療曾接受含irinotecan之細胞毒性療法治療失敗且具有上皮生長因子接受體(EGFR)表現型KRAS野生型轉移性大腸直腸癌患者。\r\n與5-fluorouracil、folinic acid及bevacizumab合併治療，做為轉移性大腸癌或直腸癌患者的第一線治療藥物。\r\n與capecitabine合併治療，做為轉移性大腸直腸癌患者的第一線治療藥物。",
    "劑型": "270注射劑",
    "包裝": "2毫升、5毫升及15毫升塑膠小瓶裝 各100支以下盒裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "主成分略述": [
        "IRINOTECANHYDROCHLORIDETRIHYDRATE"
    ],
    "限制項目": "02輸　入",
    "申請商名稱": "1504401100  輝瑞大藥廠股份有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F020034000  PFIZER (PERTH) PTY LIMITED",
        "製造廠廠址": "TECHNOLOGY PARK,15 BRODIE HALL DRIVE,BENTLEY WA 6102,AUSTRALIA.",
        "製造廠公司地址": "",
        "": ""
    },
    "CCC號列": "30049071005 抗癌藥Anti-cancer preparations",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200037710",
            "成分名稱": "IRINOTECAN HYDROCHLORIDE TRIHYDRATE",
            "含量描述": "",
            "含量": "20.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Campto 藥輸022473-103-04-21.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022473&Seq=012&Type=9"
        },
        {
            "title": "Campto_外盒包裝-104-09-22(廠商自行上傳).pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022473&Seq=015&Type=8"
        }
    ]
}